{
  "nctId": "NCT03076515",
  "briefTitle": "Migraine Treatment With Nerivio Migra Neurostimulation Device",
  "officialTitle": "A Prospective, Randomized, Double-blind, Sham Controlled Multi-center Clinical Trial, Migraine Headache Treatment With Nerivio Migra Neurostimulation Device",
  "protocolDocument": {
    "nctId": "NCT03076515",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-02-14",
    "uploadDate": "2019-09-10T08:19",
    "size": 2028922,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03076515/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 120,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-04-02",
    "completionDate": "2018-04-01",
    "primaryCompletionDate": "2018-01-31",
    "firstSubmitDate": "2017-03-07",
    "firstPostDate": "2017-03-10"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Patient is 18-75 years old.\n2. Patient meeting the ICHD-3 diagnostic criteria for migraine with and without aura.\n3. Patients reporting 2-8 migraine attacks per month.\n4. Patient must be able and willing to comply with the protocol.\n5. Patient must be able and willing to provide written informed consent.\n6. Male or non-pregnant / non-lactating female (NOTE: Females of child bearing potential must have a negative pregnancy test) and must be willing to use adequate contraceptive means during the study\n\nExclusion Criteria:\n\n1. Has other significant pain problem that in the opinion of the investigator may confound the study assessments\n2. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator).\n3. Known uncontrolled epilepsy.\n4. Use of Cannabis including medical use.\n5. Has chronic migraine (more than 15 headache days per month).\n6. Changed usage or dosage of migraine preventive medications in the last two months\n7. Has undergone nerve block (occipital or other) in the head or neck within the last 2 weeks.\n8. Is participating in any other clinical study. -",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With Pain Relief 2 Hours Post Treatment",
        "description": "Percentage of participants reporting pain relief from pain (pain reduction from 3 or 2 to 1 or 0 or pain reduction from 1 to 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks",
        "timeFrame": "2 hours post treatment"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:54.876Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}